BioNTech's BNT113 misses Phase III PFS endpoint in HPV16-positive head and neck cancer. Read the full trial update and what ...
Roche secures exclusive worldwide license to Rona Therapeutics' ALK7 RNAi obesity therapy in a deal worth up to $1.16B. Read ...
MicuRx will out-license preclinical ADC MRX-23 to ClearideBio, plus a STOPIN platform deal, worth up to USD 974 million. Read the full deal breakdown now.
Visara licenses VIS-102 nerve growth factor therapy for neurotrophic keratitis in a USD 111m deal. Read the full story on ...
Undecimal Bio raises $18M seed funding to extend siRNA delivery beyond the liver. Discover how this biotech's DELiveri ...
Mirum's Livmarli (maralixibat) significantly reduced cholestatic pruritus vs placebo in the Phase III EXPAND pediatric study.
Sloan-Kettering Institute gets a $1.5M FDA grant to map therapeutic targets in ultra-rare sarcomas. Learn how it may advance ...
Remigromig met the non-inferiority endpoint vs ranibizumab in the BRUNELLO DME trial, but PDR adverse events were higher.
Massachusetts General Hospital will test vitamin K2 drug EPN-701 in a Phase II calciphylaxis trial funded by a $2.46 million ...
Enodia Therapeutics and Pfizer sign a research and license deal worth over $500M to develop Sec61 translocon inhibitors. Read ...
Explore how iOnctura's roginolisib locks PI3Kδ in an inactive state and shows 20.8-month median survival in metastatic uveal melanoma. Read the full study.
Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results